BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 23358903)

  • 1. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
    Greenberg S; Rugo HS
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: disease entity or title of convenience?
    Carey L; Winer E; Viale G; Cameron D; Gianni L
    Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising therapeutic options in triple-negative breast cancer.
    Bilici A; Arslan C; Altundag K
    J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: is there a treatment on the horizon?
    Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
    Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting triple-negative breast cancer: optimising therapeutic outcomes.
    Gelmon K; Dent R; Mackey JR; Laing K; McLeod D; Verma S
    Ann Oncol; 2012 Sep; 23(9):2223-2234. PubMed ID: 22517820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options in triple negative breast cancer.
    Rodler E; Korde L; Gralow J
    Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
    Gonçalves A; Sabatier R; Charafe-Jauffret E; Gilabert M; Provansal M; Tarpin C; Extra JM; Viens P; Bertucci F
    Bull Cancer; 2013 May; 100(5):453-64. PubMed ID: 23695030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging targeted therapies in triple-negative breast cancer.
    Crown J; O'Shaughnessy J; Gullo G
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi56-65. PubMed ID: 23012305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: an unmet medical need.
    Hudis CA; Gianni L
    Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple negative breast cancer: therapeutic and prognostic implications.
    Brady-West DC; McGrowder DA
    Asian Pac J Cancer Prev; 2011; 12(8):2139-43. PubMed ID: 22292666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.
    André F; Zielinski CC
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi46-51. PubMed ID: 23012302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in triple negative breast cancer.
    Reeder-Hayes KE; Carey LA; Sikov WM
    Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of triple negative breast cancer.
    Oakman C; Viale G; Di Leo A
    Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.